DaVita Supports Extended Kidney Care Initiative for Improved Patient Outcomes and Savings
- DaVita supports the extension of the Kidney Care Choices Model, enhancing patient engagement and health outcomes.
- The company has doubled its value-based care initiatives, managing 22 Kidney Contracting Entities for improved patient care.
- DaVita aims to reduce hospitalizations and improve mortality rates, promoting higher quality standards in kidney care.
DaVita Champions Extended Kidney Care Initiative for Enhanced Patient Outcomes
DaVita Inc., a frontrunner in kidney care services, expresses robust support for the Center for Medicare and Medicaid Innovation’s (CMMI) recent decision to extend the Kidney Care Choices (KCC) Model for an additional year. This initiative aligns seamlessly with DaVita's longstanding commitment to value-based care, a cornerstone of its operations for the past two decades. Misha Palecek, DaVita's chief transformation officer, emphasizes that the KCC Model fosters comprehensive and collaborative care, empowering patients and promoting engagement. This approach not only enhances health outcomes but also offers potential long-term savings for the healthcare system.
The KCC Model marks a significant evolution in kidney care, and DaVita has been instrumental in its implementation. Since launching 11 value-based care arrangements in 2022, the company has doubled its initiatives, now managing 22 Kidney Contracting Entities (KCEs). These arrangements have a measurable impact on patient care, evidenced by reports indicating increased kidney transplants and improved access to dialysis. Additionally, there is a notable rise in home dialysis patients, reflecting a shift towards more patient-centric care models. As DaVita continues to expand its reach, it serves approximately 282,000 patients across 3,173 outpatient dialysis centers worldwide, with 2,661 facilities located within the United States.
DaVita’s commitment extends beyond immediate patient care; the company is dedicated to reducing hospitalizations and improving mortality rates through its initiatives. By encouraging the kidney care community to adopt higher quality standards, DaVita enhances healthcare access and overall service delivery. The transformation of care throughout the kidney health journey—from slowing disease progression to supporting transplantation and providing acute hospital care—is a testament to DaVita's innovative approach in the industry. For further details on DaVita’s Integrated Kidney Care programs, stakeholders can visit DaVita.com/Innovation.
In addition to its support for the KCC Model, DaVita’s strategic growth in value-based care arrangements reflects a broader trend in the healthcare sector toward more integrated, outcome-focused models. The company remains a pivotal player in advancing kidney care standards, striving to improve patient experiences and outcomes while optimizing resource utilization. As it navigates these developments, DaVita reinforces its position as a leader in transforming kidney health care delivery.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

